Gsk (GSK) Total Current Liabilities (2009 - 2026)
Gsk (GSK) posted quarterly Total Current Liabilities of -$28.9 billion for Q2 2026, down 6.28% year-over-year from -$30.8 billion in Q2 2025, and up 4.45% quarter-over-quarter from -$30.2 billion in Q1 2026.
Gsk (GSK) Total Current Liabilities (2009 - 2026) Analysis & Trends
Gsk's Total Current Liabilities history runs 18 years deep, the most recent figure standing at -$28.9 billion for Q2 2026.
- In Q2 2026, Total Current Liabilities fell 6.28% year-over-year to -$28.9 billion; the TTM figure through Jun 2026 stood at -$28.9 billion (down 6.28% YoY), while the FY2025 annual figure was -$28.2 billion, down 201.69% from the prior year.
- Total Current Liabilities for Q2 2026 stood at -$28.9 billion, up from -$30.2 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $27.8 billion in Q4 2024, with the low at -$47.6 billion in Q2 2022.
- The 5-year median for Total Current Liabilities is -$26.7 billion (2025), against an average of -$18.2 billion.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 75.88% in 2022, then slumped 273.01% in 2023.
- Gsk's Total Current Liabilities stood at $26.8 billion in 2022, then retreated by 2.26% to $26.1 billion in 2023, then advanced by 6.5% to $27.8 billion in 2024, then plunged by 202.17% to -$28.5 billion in 2025, then dropped by 1.54% to -$28.9 billion in 2026.
- Business Quant data shows GSK's Total Current Liabilities at -$28.9 billion in Q2 2026, -$30.2 billion in Q1 2026, and -$28.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.89 Bn |
| Mar 31, 2026 | -30.24 Bn |
| Dec 31, 2025 | -28.45 Bn |
| Sep 30, 2025 | -28.79 Bn |
| Jun 30, 2025 | -27.19 Bn |
| Mar 31, 2025 | -26.24 Bn |
| Dec 31, 2024 | 27.85 Bn |
| Sep 30, 2024 | -27.88 Bn |
| Jun 30, 2024 | -25.68 Bn |
| Mar 31, 2024 | -25.18 Bn |
| Dec 31, 2023 | 26.15 Bn |
| Sep 30, 2023 | -28.36 Bn |
| Jun 30, 2023 | -27.67 Bn |
| Mar 31, 2023 | -25.16 Bn |
| Dec 31, 2022 | 26.75 Bn |
| Sep 30, 2022 | -24.69 Bn |
| Jun 30, 2022 | -47.65 Bn |
| Mar 31, 2022 | -6.74 Bn |
| Dec 31, 2021 | 31.91 Bn |
| Sep 30, 2021 | -30.90 Bn |